Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its product pipeline includes Telaprevir, a Phase 3 clinical trial product for the treatment of hepatitis C virus infection; VX-500, a Phase 1a clinical trial product for chronic HCV infection; VX-770 and VX-809, potential treatments for cystic fibrosis; VX-702, a Phase 2 clinical trial product for the treatment of rheumatoid arthritis and other inflammatory diseases; and MK-0457(VX-680) and AVN-944(VX-944), which are in Phase 2 clinical trials for the treatment of cancer. The company also markets fosamprenavir calcium, an HIV protease inhibitor through collaboration with GlaxoSmithKline, under the trade name Lexiva in the United States and under the trade name Telzir in the European Union. In addition, Vertex Pharmaceuticals has various products in preclinical stage, which include VX-813 for chronic HCV infection, VX-883 for bacterial infection, VX-689 for Cancer, and VX-509 for immune-mediated inflammatory diseases. The company has collaboration agreements with Janssen Pharmaceutica, N.V.; Cystic Fibrosis Foundation Therapeutics Incorporated; GlaxoSmithKline plc; Merck & Co., Inc.; Mitsubishi Tanabe Pharma Corporation; and Avalon Pharmaceuticals, Inc. Vertex Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, Massachusetts.